Browsing by Author "Hamuryudan V."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey
    (2012) Malhan S.; Pay S.; Ataman S.; Dalkilic E.; Dinc A.; Erken E.; Ertenli I.; Ertugrul E.; Gogus F.; Hamuryudan V.; Inanc M.; Karaaslan Y.; Karadag O.; Karakoc Y.; Keskin G.; Kisacik B.; Kiraz S.; Oksel F.; Oksuz E.; Pirildar T.; Sari I.; Soy M.; Senturk T.; Taylan A.
    Objectives: To determine the direct and indirect costs due to rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients in Turkey. Methods: An expert panel was convened to estimate the direct and indirect costs of care of patients with RA and AS in Turkey. The panel was composed of 22 experts chosen from all national tertiary care rheumatology units (n=53). To calculate direct costs, the medical management of RA and AS patients was estimated using "cost-of-illness" methodology. To measure indirect costs, the number of days of sick leave, the extent of disability, and the levels of early retirement and early death were also evaluated. Lost productivity costs were calculated using the "human capital approach", based on the minimum wage. Results: The total annual direct costs were 2,917.03 Euros per RA patient and 3,565.9 Euros for each AS patient. The direct costs were thus substantial, but the indirect costs were much higher because of extensive morbidity and mortality rates. The total annual indirect costs were 7,058.99 Euros per RA patient and 6,989.81 for each AS patient. Thus, the total cost for each RA patient was 9,976.01 Euros and that for an AS patient 10,555.72 Euros, in Turkey. Conclusion: From the societal perspective, both RA and AS have become burden in Turkey. The cost of lost productivity is higher than the medical cost. Another important conclusion is that indirect costs constitute 70% and 66% of total costs in patients with RA and AS, respectively. © Clinical and Experimental Rheumatology 2012.
  • No Thumbnail Available
    Item
    Impact of rheumatoid arthritis in Turkey: A questionnaire study
    (Clinical and Experimental Rheumatology S.A.S., 2014) Direskeneli H.; Akkoç N.; Bes C.; Çakir N.; Çefle A.; Çobankara V.; Dalkiliç E.; Dinç A.; Ertenli I.; Gül A.; Hamuryudan V.; Inanç M.; Kalyoncu U.; Karaaslan Y.; Kaşifoǧlu T.; Keser G.; Keskin G.; Kisacik B.; Kiraz S.; Masatlioǧlu S.; Onat A.M.; Özbek S.; Öztürk M.A.; Pamuk Ö.N.; Pay P.; Pirildar T.; Sayarlioǧlu M.; Şenel S.; Şentürk T.; Taşan D.; Terzioǧlu E.; Yazici A.; Yücel E.
    Objective: Unmet needs of rheumatoid arthritis (RA) patients regarding physician/patient communication, treatment preferences and quality of life issues were investigated in a Turkish survey study. Methods: The study was conducted with the contribution of 33 rheumatologists, and included 519 RA patients. The study population included patients who had been on biologic therapy for >6 months and were still receiving biologic therapy (BT group), and those who were biologic naive, but found eligible for biologic treatment (NBT group). Of the RA patients, 35.5% initially had a visit to an internal disease specialist, 25.5% to a physical therapy and rehabilitation specialist, and 12.2% to a rheumatology specialist for their RA complaints. The diagnosis of RA was made by a rheumatologist in 48.2% of patients. Results: The majority of RA patients (86.3%) visit their doctor within 15-week intervals. Most of the physician-patient communication focused on disease symptoms (99.0%) and impact of the disease on quality of life (61.8%). The proportion of RA patients who perceived their health status as good/very good/excellent was higher in the BT group than in the NBT group (74.3% vs. 51.5%, p<0.001). However, of those RA patients in the NBT group, only 24.8% have been recommended to start a biologic treatment by their doctors. With respect to dose frequency options, once-monthly injections were preferred (80%) to a bi-weekly injection schedule (8%). Conclusion: In conclusion, RA patients receiving biologic therapy reported higher rates of improved symptoms and better quality of life and seemed to be more satisfied with their treatment in our study. © Clinical and Experimental Rheumatology 2014.